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Background: Fewer than 6% patients with adenocarcinoma of the pancreas live up to five years after diagnosis.
Chemotherapy is currently the standard treatment, however, these tumors often develop drug resistance over time.
Agents for increasing the cytotoxic effects of chemotherapy or reducing the cancer cells’ chemo-resistance to the drugs
are required to improve treatment outcome. Nuclear factor kappa B (NF-kB), a pro-inflammatory transcription factor,
reportedly plays a significant role in the resistance of pancreatic cancer cells to apoptosis-based chemotherapy. This
study investigated the effect of aqueous Moringa Oleifera leaf extract on cultured human pancreatic cancer cells - Panc-1,
p34, and COLO 357, and whether it can potentiates the effect of cisplatin chemotherapy on these cells.
Methods: The effect of Moringa Oleifera leaf extract alone and in combination with cisplatin on the survival of cultured
human pancreatic cancer cells was evaluated by XTT-based colorimetric assay. The distribution of Panc-1 cells in the cell
cycle following treatment with Moringa leaf extract was evaluated by flow cytometry, and evaluations of protein levels
were via immunoblotting. Data of cell survival following combined treatments were analyzed with Calcusyn software.
Results: Moringa Oleifera leaf extract inhibited the growth of all pancreatic cell lines tested. This effect was significant in
all cells following exposure to ≥0.75 mg/ml of the extract. Exposure of Panc-1 cells to Moringa leaf extract induced an
elevation in the sub-G1 cell population of the cell-cycle, and reduced the expression of p65, p-IkBα and IkBα proteins in
crude cell extracts. Lastly, Moringa Oleifera leaf extract synergistically enhanced the cytotoxic effect of cisplatin on Panc-1
cells.
Conclusion: Moringa Oleifera leaf extract inhibits the growth of pancreatic cancer cells, the cells NF-κB signaling
pathway, and increases the efficacy of chemotherapy in human pancreatic cancer cells.
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Natural products from plants provide an important source
of new drugs and potential pharmaceutical "lead" com-
pounds. Natural products or natural product-derived drugs
include 28% of all new chemical entities launched between
1981 and 2002, and 24% of them are semi-synthetic natural
product analogues or synthetic compounds based on nat-
ural product pharmacophores [1]. Furthermore, many
anti-tumor agents in current clinical use are of natural* Correspondence: Shaharl@tasmc.health.gov.il
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reproduction in any medium, provided the ororigin, among them taxanes (docetaxel, paclitaxel), Vinca
alkaloids (vindesine, vinblastine, vincristine), anthracyclines
(idarubicin, daunorubicin, epirubicin), and others. Thus,
there is a promising future for the use of natural products
derived from plants as anti-tumor agents.
Adenocarcinoma of the pancreas, the most common
form of pancreatic cancer, is the fourth commonest
cause of cancer-related mortality worldwide [2]. This
cancer is often diagnosed at advanced stages and has a
poor prognosis, with fewer than 6% of those patients liv-
ing as long as five years after diagnosis [2]. The basis of
current pancreatic cancer therapy is targeting DNAral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agent like 5-FU or a platinum based agent [3]. Unfortu-
nately, this treatment is limited by a resistance of the
cancer cells to these therapies as well as a somatic tox-
icity [4]. The drug resistance is attributed to several
mechanisms: drugs exclusion from the cells, changes in
the enzymes metabolizing the drugs, or the cells becom-
ing more resistant to stress and apoptosis [4].
Nuclear factor kappa B (NF-κB) is an essential regula-
tor of the innate and adaptive immunity that, under
most conditions, supports proliferation and survival of
cells via inhibition of apoptosis [5]. Constitutively active
NF-κB signaling that strengthens the malignant cells’
ability to survive has been demonstrated in most tumor
cell lines as well as in a variety of patient-derived tumor
tissues, including those from pancreatic cancer [6,7].
NF-κB activation has also been directly linked to pancre-
atic cancer metastatic potential [8]. Although the reason
for its constitutive activation in malignant cells has not
been fully elucidated, suppression of NF-κB in the ma-
jority of these tumors leads to the induction of apoptosis
and the subsequent generation of cell death. In addition,
several lines of evidence indicate that NF-κB plays a sig-
nificant role in pancreatic cancer resistance to apoptosis-
based chemotherapies, leading to NF-kB being suggested
as a potential molecular target for pancreatic cancer
therapy [8].
Moringa Oleifera, Lam. (Moringaceae) is a tree that
grows widely in the tropics and subtropics of Asia and Af-
rica. Its leaves have been traditionally consumed by Asian
village people, but it is a relatively novel food material in
the western world [9]. Moringa Oleifera contains several
phytochemicals, some of which are of special interest be-
cause of their medicinal properties. Leaves of Moringa
Oleifera contain flavonoid pigments, such as kaempferol,
rhamnetin, isoquercitrin and kaempferitrin. In addition,
these leaves are rich in a group of the glycoside com-
pounds, glucosinolates and isothiocyanates [10] as well as
beta-sitosterol, glycerol-1-(9-octadecanoate), 3-O-(6'-
O-oleoyl-beta-D-glucopyranosyl), beta-sitosterol and beta-
sitosterol-3-O-beta-D-glucopyranoside, all of which have
demonstrated anti-cancer properties in-vitro [11]. An in-
vitro study using human KB cells as a cancer model has
shown that Moringa Oleifera leaf extract exerts strong
anti-tumor activity [12]. In addition, different leaf extracts
of Moringa Oleifera generate significant cytotoxic effects
on human multiple myeloma cultured cell lines [13].
The present study examined the effect of Moringa
Oleifera aqueous leaf extract on the viability and cell cycle
of cultured human pancreatic cancer cells, and evaluated
its ability to modify the expression of key proteins of the
NF-kB signaling pathway. Lastly, this study examined the
effect of combined treatments with Moringa Oleifera aque-
ous leaf extract and cisplatin chemotherapy on these cells.Methods
Preparation of Moringa Oleifera aqueous extract
Leaves of Moringa Oleifera were received from Moringa
Arava Ltd, Israel. Moringa Arava grows the Moringa
Oleifera plant in the Dead Sea area, Israel, where it is
grown in rich mineral soil. The plant derived aqueous ex-
tract tested in this study was prepared in our laboratory
by mixing 1g dried and powdered leaves of Moringa
Oleifera with 10 mL boiling water for 5 minutes. The mix-
ture was then filtered twice through a 2 μm pore sterile fil-
ter paper into a sterile tube. The aqueous extract stock
solution (100 mg/mL) was freshly prepared for each set of
experiments and stored at 4°C for up to 5 days.
Cell lines and culture conditions
Human pancreatic cancer cell lines (Panc-1 and COLO-
357) were kindly provided by Prof. Ziv Gil (Laboratory
for Applied Cancer Research, Tel Aviv Sourasky Medical
Center, Israel). Human pancreatic cancer cell line p34
[14], developed from pleural effusion of a pancreatic
cancer patient, was kindly provided by Dr. Alex Starr
(Laboratory of Lung Biology, Lung and Allergy Institute,
Tel Aviv Sourasky Medical Center, Israel). All cells were
grown in Dulbecco modified Eagle medium (DMEM)
supplemented by 10% heat-inactivated bovine serum,
4.5 g/L glucose, 200 μM L-glutamine, 10 units/ml penicil-
lin and 10 μg/mL streptomycin (Biological Industries, Beit
HaEmek, Israel). The cells were incubated at 37°C in a 5%
CO2 humidified atmosphere. The cells were harvested by
trypsin/EDTA solution with 1–2 passages per week in a
split ratio of 1:3–5. The 24-hour cell cultures were used in
all the experiments.
Colorimetric tetrazolium salt (XTT) assay for cell survival
The effect of the treatments tested on the survival of
cultured cells was evaluated by XTT-based colorimetric
assay (Biological Industries). Typically, 200 μl with 1.5–
2x103 cells per well from exponentially growing cultures
were plated in 96 micro-well flat-bottom plates. After 24
hours had elapsed, the agents tested were added in cal-
culated concentrations each in three replicate wells and
incubated for 72 hours. At the end of the experiment, a
freshly prepared mixture of XTT and an activation re-
agent (PMS) was added into each well (50 μL). Following
2 hours of incubation at 37°C, the optical density (OD)
readings were measured at 450 nm using a microplate
reader (TECAN Sunrise™ , Switzerland). The measure-
ments were repeated following 3 and 4 hours of incuba-
tion, and the time point at which the assay showed
optimal OD readings was chosen to calculate the effect
of the treatment. When more than one time point fitted
these criteria, the results for the different time points
were normalized and averaged. Cell survival following
treatment was expressed as a percentage of viable cells
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conducted at least twice, in triplicate wells each, and the
results of each experiment were averaged. The preliminary
experiments on the selected pancreatic cancer cell lines
had demonstrated that the OD readings correlated well
(r>0.97–0.99) with the number of seeded cells/well.
Analysis of synergistic effect of combined treatment
The IC50 value of each treatment was calculated on the
basis of dose–response curves produced by the XTT as-
says. In order to determine whether the combined treat-
ment is synergistic or additive, the data on cell survival
for each treatment alone and for combined treatment were
analyzed with Calcusyn software (Biosoft, Cambridge, UK)
that is based on the Chou and Talalay's equations [15]. This
software evaluates the combined effect of Moringa Oleifera
leaf extract and chemotherapeutic agents by calculating the
combination index (CI) using the following equation:




Where (D)1 and (D)2 are the doses of drug 1 and drug
2 in a mixture that inhibits the system x percent and
where (Dx)1 and (Dx)2 are the doses of the drugs that
were given individually that inhibited the system x per-
cent. According to the software, CI ≤1 indicates syner-
gism, CI = 1 indicates an additive effect, and CI ≤1
indicates drug antagonism.
Immunoblotting analysis
The cells were plated in 10-cm tissue culture dishes for
24 hours at 37°C in a 5% CO2 humidified atmosphere.
The culture medium was then replaced with a fresh
medium supplemented with Moringa Oleifera leaf extract
for 24 hours. Whole-cell protein samples for immunoblot-
ting were prepared using a proteoJET™ mammalian cell lysis
reagent according to standard protocol (Fermentas Life Sci-
ences, Thermo Fisher Scientific). The cytoplasmic and nu-
clear extracts for immunoblotting were prepared using
NucBuster™ protein extraction kit (Novagen® ,U.S.A).
Determination of the protein concentrations was
performed using the Bradford assay. Protein from
each sample (100 μg) was subjected to electrophor-
esis in 10% SDS-PAGE and transferred to pure nitro-
cellulose blotting membranes (Millipore, Bedford,
M.A, U.S.A). Membranes were blocked for 1 hour at
room temperature with Tris (hydroxymethyl) amino
methane saline (TBS) containing 0.05% Tween 20
and 5% non-fat skim milk (BD Bioscience, San Jose,
CA). The membranes were then incubated at room
temperature in phosphate-buffered solution (PBS)
containing 5% milk and the following antibodies (1:200 di-
lutions): phospho-IκBα (Cell Signaling Technology®, M.A,U.S.A), NF-κB, p65, IκBα and GAPDH (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). Membranes were
washed in TBS 0.05% Tween 20, and incubated with
either goat, anti-rabbit or rat secondary antibodies
(1:1000) conjugated to horseradish peroxidase (Santa
Cruz Biotechnology, Inc. U.S.A). Detection was by
SuperSignal® West Pico from Pierce BioLynx Inc.
(Brockville, Ontario, Canada) reagent.
Flow cytometry (FACS) analysis of cell cycle
The distribution of Panc-1 cells (intact and treated with
Moringa Oleifera leaf extract for 24 hours) in the cell
cycle was evaluated by flow cytometry. FACS analysis
was used to detect sub-diploid apoptotic cells, and try-
pan blue assay was used to discriminate between nec-
rotic and apoptotic cells. The cells (0.5-1.0x106 cells/
plate) were collected following treatment, washed with
cold PBS, fixed in ice cold 70% ethanol and kept at −20°C
for 24–48 hours. The pellets were washed in cold PBS
and suspended in PBS containing 0.1% Triton-X and
30 mg/mL DNAse-free RNAse A (Sigma-Aldrich, Israel)
for 6 hours at room temperature. Approximately one mi-
nute before the cells were analyzed, propidium iodide
(Sigma) in PBS was added at a final concentration of
10 μg/mL. The samples were analyzed using a FACSCallibur
instrument (BD Bioscience). Data were processed with BD
Bioscience software.
Statistical analysis
The results for each variant of treatment in these experi-
ments were represented as an average of 2–4 experi-
ments, and each arm was performed in triplicate. The
mean values and standard errors were calculated for
each time point from the pooled normalized data. The
statistical significance of the difference between groups
was determined by the two-tailed Student’s t-test. Values
of p < 0.05 were considered significant.
Results
The antiproliferative and apoptotic effects of the aque-
ous leaf extract of Moringa oleifera have been previously
evaluated in KB cultured human tumor cells [12], where
the extract was used in up to 200 μg/mL final concentra-
tion. Thus, for our survival experiments of cultured pan-
creatic cancer cells we started looking for an effect
around 0.1 mg/mL and upraised it according to our
results.
Effect of Moringa Oleifera leaf extract on survival and cell
cycle of pancreatic cancer cells
The effect of Moringa Oleifera leaf extract (0.1-2.0 mg/mL)
on the survival of cultured pancreatic cancer cells was eval-
uated following exposure for 72 hours. As shown in
Figure 1, Moringa extract inhibited the growth of all
Figure 1 Effect of Moringa Oleifera leaf extract on the viability of Panc-1, COLO 357 and p34 pancreatic cancer cells. The cells were
plated in 96-well plates and treated in triplicates with Moringa Oleifera leaf extract for 3 days. Cell survival was assessed using XTT-based cell
proliferation assay, and is indicated after normalization to the control group. The significance of the effect is indicated as *p ≤ 0.05 and
**p ≤ 0.001.
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to the treatment (IC50 = 1.1 mg/ml) compared to COLO
357 (IC50 =1.8 mg/ml) and p34 cells (IC50 = 1.5 mg/ml).
There was a significant inhibition of Panc-1 cell survival
at an extract concentration of 0.75 mg/mL. There was also
a significant inhibitory effect at a higher concentration
(1.5 mg/mL) in the two other cell lines. Moreover, treat-
ment with 2 mg/mL Moringa extract resulted in a 98%
reduction of Panc-1 cell survival.
We also evaluated the distribution of Panc-1 cells in the
cell cycle following 24 hours exposure to Moringa Oleifera
leaf extract using flow cytometry analysis of propidium
iodide-stained cells. It revealed a dose-dependent signifi-
cant increase of the percentage of cells in the sub-G1
phase, characterized by a very low DNA content, following
Moringa extract treatment (Figure 2A&B). This indicated a
fragmentation of the DNA as a result of progressive cell
apoptosis. Importantly, Moringa extract treatment also in-
duced significant (p < 0.05) apoptosis in Panc-1 cancer cells
at the minimal evaluated concentration of 0.25 mg/mL.
The induction of apoptosis was especially high (up to 30%)
at a concentration of 0.75 mg/mL.
Effect of Moringa Oleifera leaf extract on NF-κB signaling
pathway in pancreatic cancer cells
Moringa Oleifera leaf extract treatment of Panc-1 cells
down-regulated the expression of key NF-κB signaling
pathway proteins (Figure 3). The treatment of the cells
with 0.25 mg/mL extract for 24 hours resulted in a
down-regulation of p65, phospho-IκBα and IκBα pro-
teins levels compared to untreated cells (Figure 3A).
Treatments with 0.75 and 1.5 mg/mL Moringa extractreduced or eliminated more significantly the presence of
all three proteins of the NF-κB signaling pathway. More-
over, p65 protein subunit levels have decreased in Panc-1
cells nuclei as a result of treatments with 0.1 - 1.5 mg/mL
Moringa extract. These data suggest that Moringa extract
attenuated pancreatic cancer cell’s survival ability, at least
in part, by targeting the NF-κB signaling pathway.
Combined effect of Moringa Oleifera leaf extract and
cisplatin
Based on the ability of Moringa extract to inhibit the
NF-κB signaling pathway, we hypothesized that its ex-
tract treatment would sensitize pancreatic cancer cells to
chemotherapy. We therefore tested the cytotoxic effect
of several combinations of Moringa Oleifera leaf extract
with cisplatin on Panc-1 cells. Since a synergistic effect
was expected, both the agents were used in the concen-
trations of a low inhibitory effect on proliferation of
Panc-1 cells. As shown in Figure 4, all the tested combi-
nations demonstrated an inhibitory effect higher than
the effects of each agent alone. The analysis of these data
by Calcusyn software, presented in Figure 4 and summa-
rized in the Table 1, clearly demonstrated that the com-
bined Moringa Oleifera leaf extract and cisplatin
regimen resulted in strong synergistic (CI = 0.1–0.3) or
synergistic (CI = 0.3–0.7) effects.
Discussion
The results of this study show that Moringa Oleifera leaf
extract can significantly inhibit the growth of cultured
human pancreatic carcinoma cells as well as its cell-
cycle progression, in a concentration-dependent manner.
Figure 2 Effect of Moringa Oleifera leaf extract on the distribution of Panc-1 cells in the cell cycle. (A) Representative histograms of cell
distribution following Moringa Oleifera leaf extract treatments. (B) Data summarized from three independent experiments (%). The cells were
treated with the extract for 24 hours, collected, washed and fixed in 70% ice-cold ethanol. Prior to the analysis, the cells were suspended in 0.1%
Triton-X with 30 mg/ml DNAse-free RNAse A for 6 hrs. Propidium iodide was added several minutes before cell analysis by flow cytometry. The
significance of the effect, relatively to non-treated cells (control), is indicated as *p ≤ 0.05 and **p ≤ 0.001.
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100% following exposure to 2 mg/mL of Moringa extract
(Figure 1). To the best of our knowledge, this is the first
time that Moringa Oleifera was shown to have an effect
on pancreatic carcinoma cells. The exposure of Panc-1
cells to Moringa Oleifera leaf extract also reduced the
overall expression of key NF-κB family proteins in the
cells, as well as the levels of p65 protein subunit in the cell
nuclei (Figure 3). Consequently, this extract could inhibit
the NF-κB signaling cascade execution of target gene
transcription. Active NF-κB signaling was shown to
strengthen the pancreatic cancer cell’s ability to sur-
vive, and that suppression of NF-κB leads to inductionFigure 3 Effect of Moringa Oleifera leaf extract on the expression of p
in crude lysates of the cells treated with Moringa Oleifera leaf extract (0–1.5
cells treated with Moringa Oleifera leaf extract. Protein expression was analy
the quantity of standard proteins in the samples tested.of apoptosis and thus generation of cell death [8]. In-
hibition of the NF-κB signaling cascade by Moringa ex-
tract explains, at least in part, its attenuating effect on
the survival of pancreatic cancer cells, as observed on
the viability assay (Figure 1).
Several lines of evidence indicate that NF-κB plays a sig-
nificant role in the resistance of pancreatic cancer to
apoptosis-based chemotherapies. Therefore, the NF-κB
signaling pathway was suggested as a potential molecular
target for combined therapy of pancreatic cancer [8,16].
Cisplatin is a platinum-based chemotherapeutic agent that
is known to have a minimal clinical efficacy in pancreatic
cancer due to tumor chemoresistance mechanisms [4]. It65 NF-kB, IkB and p-IkB proteins in Panc-1. (A) Protein expressions
mg/mL) for 24 hours. (B) Expression of p65 in nuclear extracts of the
zed by Western blot. GAPDH and ß-actin were used to demonstrate
Figure 4 Combined treatments effect of Moringa Oleifera leaf
extract with cisplatin on the viability of Panc-1 cells. (A) Cell
viability following treatments of Moringa Oleifera leaf extract,
cisplatin and combined treatments of increasing concentrations of
the extract and cisplatin for 3 days. (B) Normalized isobologram of
Moringa Oleifera leaf extract with cisplatin treatments shown in
compound A. (C) Median-effect plot curve of Moringa Oleifera leaf
extract, cisplatin and Moringa Oleifera leaf extract with cisplatin
shown in compound A. The cells were treated with each agent
alone or in combination for 3 days. Cell viability was evaluated using
XTT-based cell proliferation assay. Data was analyzed by
Calcusyn software.
Table 1 Calculated Combination Index (CI) of the effect of
combined treatments with Moringa Oleifera leaf extract
and cisplatin on Panc-1 cells viability










The cells were treated as described in Figure 4. Cell viability was evaluated
using XTT-based cell proliferation assay. Data was analyzed using
Calcusyn software.
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creased efficacy of cisplatin may be achieved by NF-κB in-
hibitors in cancer cells [17,18]. Therefore, we hypothesizedthat the effect of Moringa Oleifera leaf extract on the in-
hibition of the NF-κB pathway may increase the efficacy of
cisplatin. As shown in Figure 4 and summarized in Table 1,
combined therapy of Moringa Oleifera leaf extract with cis-
platin demonstrated strong (CI = 0.1–0.3) or moderate
(CI = 0.3–0.7) synergistic effects in Panc-1 cells, re-
spectively. This indicates that the treatment of pancre-
atic cancer with cisplatin in combination with Moringa
Oleifera leaf extract may be a clinical therapeutic op-
tion for this chemoresistant cancer.
The past decade has witnessed the establishment of
herbal medicine as a rich source of new "western medicine"
drugs for multiple conditions, including cancer. These
herbs are often traditionally consumed by particular popu-
lations, presenting an advantage in terms of laying rest to
toxicity concerns. Herbs and their bioactive metabolites
have been reported to be anti-neoplastic both in ex-
perimental and clinical studies [19,20]. Moringa Oleifera
leaves contain flavonoid pigments, such as kaempferol,
rhamnetin, isoquercitrin and kaempferitrin. Flavonoid com-
pounds have various biological activities, including anti-
inflammatory and anti-cancer ones [21], and may be
mediating, at least in part, the effects shown here. In addition,
the Moringa Oleifera leaves are rich in a group of the glyco-
side compounds, glucosinolates and isothiocyanates [10], as
well as in beta-sitosterol, glycerol-1-(9-octadecanoate),
3-O-(6'-O-oleoyl-beta-D-glucopyranosyl), beta-sitosterol and
beta-sitosterol-3-O-beta-D-glucopyranoside, all of which
have demonstrated anti-cancer properties in-vitro [11] and
may have also contributed to the effects we exhibit. Since
this work does not include the isolation of bioactive
compounds from the Moringa Oleifera leaf extract, we
are not able to propose one or more specific active
compounds to be mediating the cellular anti-cancer ef-
fects demonstrated in our results. Moreover, it is pos-
sible that our findings can be attributed to additive or
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the extract and not to a single one. Further research on
anti-cancer effects of specific bioactive metabolites derived
from Moringa Oleifere is warranted.
Toxicity has been a limiting factor in clinical pancre-
atic cancer treatment: combined therapy with cisplatin
and gemcitabine has shown promising results in phase II
and III trials, but it was followed by severe toxicity and
therefore has not been approved as a standard of care
[4]. This should not be the case regarding Moringa
Oleifera Lam, since an acute toxicity test carried out
using male Wistar albino mice, estimated the LD(50) of
orally administered aqueous leaf extract of Moringa
oleifera Lam. to be around 1585 mg/kg for a single ad-
ministration [22]. The aqueous leaf extract of Moringa
oleifera is, therefore, considered relatively safe when ad-
ministered orally and its acquisition of permission for
clinical use highly probable.
Still, future studies need to be conducted to evaluate
and quantify the therapeutic index of Moringa Oleifera
leaf extract applicable to pancreatic cancer patients in
the clinical setting.
Conclusions
Moringa Oleifera leaf extract inhibits the NF-κB signal-
ing pathway and increases the efficacy of chemotherapy
in human pancreatic cancer cells.
Abbreviations
NF-κB: Nuclear factor kappa-B; XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide; CI: Combination Index; PBS: Phosphate-
buffered solution; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase;
OD: Optical density.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
LB planned the study’s experiments, conducted the cell culture experiments,
analyzed the signaling assays and prepared the manuscript. SLA, AR and AV
performed the statistical analysis and data calculations. GE and IR assisted
with the manuscript. SLA conceived the study and gave final approval of the
manuscript. All authors read and approved the final manuscript.
Financial support
This study was supported by the Chaya and Kadish Shermeister Endowment.
Received: 21 February 2013 Accepted: 8 August 2013
Published: 19 August 2013
References
1. Newman DJ, Cragg GM, Snader KM: Natural products as sources of new
drugs over the period 1981–2002. J Nat Prod 2003, 66:1022–1037.
2. Hariharan D, Saied A, Kocher HM: Analysis of mortality rates for pancreatic
cancer across the world. HPB (Oxford) 2008, 10:58–62.
3. Oberstein PE, Wasif Saif M: First-line treatment for advanced pancreatic
cancer. J Pancreas (Online) 2011, 12:96–100.
4. Greenhalf W, Thomas A: Combination therapy for the treatment of
pancreatic cancer. Anticancer Agents Med Chem 2011, 11:418–426.
5. Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat
Immunol 2002, 3:221–227.
6. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 2004,
6:203–208.7. Van Waes C: Nuclear factor-kappaB in development, prevention, and
therapy of cancer. Clin Cancer Res 2007, 13:1076–1082.
8. Holcomb B, Yip-Schneider M, Schmidt CM: The role of nuclear factor
kappaB in pancreatic cancer and the clinical applications of targeted
therapy. Pancreas 2008, 36:225–235.
9. Shih MC, Chang CM, Kang SM, Tsai ML: Effect of different parts (leaf, stem
and stalk) and seasons (summer and winter) on the chemical
compositions and antioxidant activity of Moringa Oleifera. Int J Mol Sci
2011, 12:6077–6088.
10. Bose CK: Possible role of Moringa Oleifera Lam. root in epithelial ovarian
cancer. Med Gen Med 2007, 9:26.
11. Guevara AP, Vargas C, Sakurai H, Fujiwara Y, Hashimoto K, et al: An anti-tumor
promoter from Moringa Oleifera Lam. Mutat Res 1999, 440:181–188.
12. Sreelatha S, Jeyachitra A, Padma PR: Antiproliferation and induction of
apoptosis by Moringa Oleifera leaf extract on human cancer cells.
Food Chem Toxicol 2011, 49:1270–1275.
13. Parvathy MVS, Umamaheshwari A: Cytotoxic effect of Moringa Oleifera leaf
extracts on human multiple myeloma cultured cell lines. Trends in
Medical Research 2 2007, 2(1):44–50.
14. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D, Ben-
Yosef R: Curcumin augments gemcitabine cytotoxic effect on pancreatic
adenocarcinoma cell lines. Cancer Invest 2007, 25:411–418.
15. Chou T-C, Talalay P: Analysis of combined drug effect: a new look at a
very old problem. Trends Pharmacol Sci 1983, 4:150–154.
16. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, et al: Restoring
apoptosis in pancreatic cancer cells by targeting the nuclear factor-kB
signaling pathway with the anti-epidermal growth factor antibody IMC-
C225. J Gastrointest Surg 2003, 7:37–43.
17. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, et al: Inhibition of
NF-kappaB increases the efficacy of cis-platin in in vitro and in vivo
ovarian cancer models. J Biol Chem 2004, 279:23477–23485.
18. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D: Biological and
chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced
apoptosis. Mol Carcinog 2005, 44:51–59.
19. Wu M, Yao B: Advances in TCM treatment of gastric cancer and studies
on the apoptosis. J Tradit Chin Med 2002, 22:303–307.
20. Engdal S, Klepp O, Nilsen OG: Identification and exploration of herb-drug
combinations used by cancer patients. Integr Cancer Ther 2009, 8:29–36.
21. Lee ER, Kang GH, Cho SG: Effect of flavonoids on human health: old
subjects but new challenges. Recent Pat Biotechnol 2007, 1(2):139–150.
22. Awodele O, Oreagba IA, Odoma S, da Silva JA, Osunkalu VO: Toxicological
evaluation of the aqueous leaf extract of Moringa oleifera Lam.
(Moringaceae). J Ethnopharmacol 2012, 139(2):330–336.
doi:10.1186/1472-6882-13-212
Cite this article as: Berkovich et al.: Moringa Oleifera aqueous leaf
extract down-regulates nuclear factor-kappaB and increases
cytotoxic effect of chemotherapy in pancreatic cancer cells. BMC
Complementary and Alternative Medicine 2013 13:212.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
